Tempus AI (NASDAQ:TEM) Given Buy Rating at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reiterated by equities research analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $80.00 price objective on the stock. BTIG Research‘s price objective would suggest a potential upside of 19.12% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald initiated coverage on shares of Tempus AI in a research report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 price target on the stock. Stifel Nicolaus dropped their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research note on Monday, August 3rd. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Finally, Lake Street Capital lowered shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Eleven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and a consensus price target of $72.47.

Tempus AI Trading Down 0.7%

Shares of Tempus AI stock traded down $0.45 during mid-day trading on Monday, hitting $67.16. 3,767,579 shares of the stock were exchanged, compared to its average volume of 6,179,195. The company has a 50-day simple moving average of $69.24 and a 200 day simple moving average of $57.26. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI has a twelve month low of $40.77 and a twelve month high of $93.38. The stock has a market capitalization of $12.12 billion, a price-to-earnings ratio of -46.64 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period last year, the company earned ($0.22) earnings per share. The company’s quarterly revenue was up 21.6% on a year-over-year basis. Research analysts forecast that Tempus AI will post -1.43 EPS for the current year.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the completion of the transaction, the chief executive officer owned 200,000 shares in the company, valued at approximately $8,412,000. This trade represents a 55.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the transaction, the executive vice president owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This trade represents a 13.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 1,280,965 shares of company stock worth $80,397,564. Company insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Large investors have recently made changes to their positions in the business. Eagle Health Investments LP bought a new position in shares of Tempus AI during the 1st quarter valued at about $11,588,000. Aristotle Atlantic Partners LLC purchased a new stake in shares of Tempus AI in the first quarter worth approximately $6,179,000. Headlands Technologies LLC purchased a new stake in shares of Tempus AI in the second quarter worth approximately $2,689,000. Odyssean LLC acquired a new position in Tempus AI in the second quarter worth approximately $897,000. Finally, Canal Insurance CO increased its holdings in Tempus AI by 100.0% in the first quarter. Canal Insurance CO now owns 40,000 shares of the company’s stock worth $1,809,000 after buying an additional 20,000 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: EU regulatory certification: Tempus announced that its xR RNA sequencing assay received Class C certification under the European Union’s In Vitro Diagnostic Regulation. The certification covers solid-tumor profiling and supports the company’s ability to market the test for clinical management in Europe, potentially expanding adoption and revenue opportunities. Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
• Positive Sentiment: AI drug-development collaboration: Tempus is participating in a strategic collaboration with Pathos AI and Bristol Myers Squibb focused initially on Alzheimer’s disease and other neurological conditions. The agreement reinforces Tempus’ role in AI-enabled drug development and could create longer-term data and collaboration opportunities, although financial terms were not provided. Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst support: BTIG reaffirmed its “buy” rating and maintained an $80 price target, implying meaningful upside from the stock’s recent level. BTIG Research stock recommendations
• Neutral Sentiment: Earnings setup: Zacks expects Tempus to have favorable conditions for beating estimates in its upcoming report. A beat could support the shares, but the article reflects expectations rather than reported results. Tempus AI expected earnings estimates
• Negative Sentiment: Cash-burn concerns: Continued cash consumption could pressure Tempus’ valuation and increase the need for financing, particularly because the company remains unprofitable and has a high debt-to-equity ratio. What Happens To Tempus AI Stock If Its Cash Burn Continues?
• Neutral Sentiment: Short-interest data: The latest report lists no measurable short interest and a zero-day short-interest ratio, suggesting little evidence of short-covering activity as a current catalyst.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.